Group 1 - The acrylic acid concept sector increased by 2.56%, ranking fifth among concept sectors, with 13 stocks rising, including Xingye Co., which hit the daily limit [1] - Notable stock performances within the acrylic acid sector include Bohai Chemical, Akerley, and Guoen Co., which rose by 6.42%, 4.84%, and 4.10% respectively [1] Group 2 - The acrylic acid concept sector saw a net inflow of 231 million yuan from main funds, with 10 stocks receiving net inflows, and 7 stocks exceeding 10 million yuan in net inflows [2] - Xingye Co. led the net inflow with 105 million yuan, followed by Tianlong Group, Bohai Chemical, and Satellite Chemical with net inflows of 75.79 million yuan, 35.55 million yuan, and 20.25 million yuan respectively [2] Group 3 - In terms of fund inflow ratios, Xingye Co., Bohai Chemical, and Hongqiang Co. had the highest net inflow rates at 38.39%, 13.27%, and 8.28% respectively [3] - The acrylic acid concept fund inflow rankings show that Xingye Co. had a daily increase of 10.02% with a turnover rate of 6.04%, while Tianlong Group and Bohai Chemical had increases of 1.70% and 6.42% respectively [3][4]

2023年6月8日，本立科技发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为：以公司 现有总股本70,680,000股为基数，向全体股东每10股派1.500000元人民币现金，同时，以资本公积金向 全体股东每10股转增5.000000股。本次权益分派股权登记日为2023年6月15日，除权除息日为2023年6月 16日。 本立科技于2021年9月14日在深交所创业板上市，发行股票数量为1768万股，占发行后总股本的比例为 25.01%，发行价格为42.50元/股，保荐机构为长城证券（002939）股份有限公司，保荐代表人为刘逢 敏、郑益甫。上市首日，本立科技盘中创下股价高点112.99元。 中国经济网北京8月14日讯今日，本立科技（301065）(301065.SZ)收报24.25元，跌幅6.69%，目前该股 股价低于发行价。 本立科技公开发行新股的发行费用合计6814.48万元，其中长城证券股份有限公司获得保荐、承销费用 (不含增值税)4724.91万元。 本立科技募集资金总额为7.51亿元，扣除发行费用后，募集资金净额为6.83亿元。本立科技最终募集资 金净额比原计划多2.07亿元。本立 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688302 | 海创药业 | 66.58 | 10.43% | 11.28万 | 7.71亿 | | 300584 | 海辰药业 | 53.05 | 6.72% | 20.99万 | 11.15亿 | | 300436 | 广生堂 | 145.59 | 6.39% | 13.98万 | 20.20亿 | | 002365 | 永安药业 | 21.86 | 5.81% | 73.91万 | 16.22亿 | | 002826 | 易明医药 | 23.50 | 5.33% | 30.41万 | 7.16亿 | | 601089 | 福元医药 | 31.88 | 4.70% | 26.63万 | 8.66亿 | | 688658 | 倪康药业 | 32.85 | 4.29% | 9.10万 | 2.9867 | | 002675 | 东诚药业 | 18.29 | 4.22% | 34.99万 | 6.39 Z | | 002437 | 营衡药业 | 3 ...

Group 1 - The company, Benli Technology (301065.SZ), focuses on the research, production, and sales of pharmaceutical intermediates, pesticide intermediates, and new material intermediates [1] - The current main products in the pharmaceutical intermediate sector are primarily used in the field of quinolone drug intermediates [1] - The company does not have any innovative drug products at present [1]

Group 1 - The acrylic acid concept sector increased by 2.35%, ranking third in terms of growth among concept sectors, with nine stocks rising, including Shenyang Chemical, which hit the daily limit, and Wanhua Chemical, Huayi Group, and Benli Technology, which rose by 8.29%, 7.41%, and 4.28% respectively [1][2] - The main capital inflow into the acrylic acid concept sector was 875 million yuan, with six stocks receiving net inflows, led by Wanhua Chemical with a net inflow of 849 million yuan, followed by Guoen Co., Shenyang Chemical, and Satellite Chemical [2][3] - The net inflow ratios for Guoen Co., Wanhua Chemical, and Shenyang Chemical were 12.53%, 12.32%, and 12.09% respectively, indicating strong investor interest in these stocks [3] Group 2 - The top gainers in the acrylic acid concept sector included Wanhua Chemical, which rose by 8.29%, and Shenyang Chemical, which increased by 10.05%, while Guoen Co. experienced a slight decline of 0.29% [3][4] - The overall performance of the acrylic acid concept sector was positive, contrasting with other sectors such as animal vaccines and avian influenza, which saw declines of 0.96% and 0.90% respectively [2][4] - The trading volume and turnover rates for the leading stocks in the acrylic acid sector were notable, with Wanhua Chemical achieving a turnover rate of 3.77% and Shenyang Chemical at 8.40% [3]

Group 1 - The acrylic acid concept sector declined by 0.80%, ranking among the top declines in the concept sector, with companies like AkzoNobel, Tianlong Group, and Guoen Co. experiencing significant drops [1] - Among the acrylic acid concept stocks, three companies saw price increases, with Baolijia, Bohai Chemical, and Hongqiang Co. rising by 0.60%, 0.46%, and 0.24% respectively [1] - The acrylic acid concept sector experienced a net outflow of 213 million yuan in main funds, with Wanhua Chemical leading the outflow at 145 million yuan [2] Group 2 - The top gainers in the concept sector included rare earth permanent magnets with a rise of 5.64%, while the housing inspection sector fell by 1.47% [2] - The main funds saw inflows into satellite chemicals, Xingye Co., and Shenyang Chemical, with net inflows of 42.6 million yuan, 6.8 million yuan, and 2.6 million yuan respectively [2][3] - The acrylic acid concept stocks with the highest net outflows included Tianlong Group and Huayi Group, with outflows of 63.7 million yuan and 18.8 million yuan respectively [2]

证券代码：301065 证券简称：本立科技 公告编号：2025-023 浙江本立科技股份有限公司 2024年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 根据《深圳证券交易所上市公司自律监管指引第9号——回购股份》等相关 规定，浙江本立科技股份有限公司（以下简称"公司"或"本公司"）回购专用 证券账户中的股份不参与本次权益分派。公司2024年年度权益分派方案为：以总 股本扣除已回购股份2,847,362股后的103,172,638股为基数，向全体股东每10股 派发现金红利人民币2.00元，实际派发现金红利总额=103,172,638股×2.00元 /10股=20,634,527.60元（含税）。本次权益分派实施后计算除权除息价格时， 按总股本（含回购股份）折算的每10股现金红利（含税）=现金分红总额/总股本 *10=20,634,527.60/106,020,000*10=1.946286元（保留六位小数，最后一位直 接截取，不四舍五入）。本次权益分派实施后除权除息参考价=除权除息日前一 交易日收盘价-按总股本（含回购股份） ...

Group 1 - The acrylic acid concept sector rose by 1.88%, ranking 7th among concept sectors, with 8 stocks increasing in value, including Bohai Chemical which hit the daily limit, and Shuangxiang Co., Shenyang Chemical, and Baolijia showing gains of 4.49%, 2.93%, and 2.59% respectively [1] - The main inflow of funds into the acrylic acid concept sector was 158 million yuan, with Bohai Chemical leading the net inflow at 86.73 million yuan, followed by Wanhua Chemical, Satellite Chemical, and Rike Chemical with net inflows of 71.24 million yuan, 17.03 million yuan, and 11.80 million yuan respectively [2] - In terms of net inflow ratios, Bohai Chemical, Shenyang Chemical, and Rike Chemical had the highest ratios at 14.08%, 5.97%, and 5.93% respectively [3] Group 2 - The top stocks in the acrylic acid concept sector included Bohai Chemical with a daily increase of 10.10% and a turnover rate of 13.09%, while Wanhua Chemical increased by 1.14% with a turnover rate of 0.77% [3][4] - Stocks that experienced declines included Tianlong Group, which fell by 0.98%, and Benli Technology and Acoly, both down by 0.35% [1][4] - The overall performance of the acrylic acid concept sector indicates a positive trend, with significant capital inflows and several stocks showing strong gains [2][3]

Group 1 - Huiyu Pharmaceutical's subsidiary received drug registration certificate for Carboxymethyl Sodium Injection, which is used for treating bleeding diseases in various medical fields [1] - Baihe Co., Ltd. announced a plan for a director to reduce holdings by up to 424,000 shares, representing 0.6625% of the total share capital [1] - Kingood Co., Ltd. received a notification from a global leading automaker for a wheel project, expected to start mass production in 2026 with a lifecycle of 10 years [1][2] Group 2 - Wanhua Chemical plans to repurchase shares worth between 300 million and 500 million yuan, with a maximum repurchase price of 99.36 yuan per share [2] - Warner Pharmaceutical's subsidiary received approval for Acetylcysteine raw material drug, primarily used for treating respiratory diseases [3] - ST Mingcheng plans to publicly transfer 45% equity of its subsidiary, aiming to optimize asset structure [4] Group 3 - Qixia Construction announced a plan to reduce up to 31.5 million shares, accounting for 3% of total share capital [5][6] - Zhejiang Rongtai intends to invest 20 million yuan to establish a wholly-owned subsidiary focused on intelligent robotics [7] - Yuandong Biological received drug registration for Chloral Hydrate Enema, used for sedation and seizure control in children [9] Group 4 - Jiemai Technology's subsidiary signed a strategic cooperation agreement with a solid-state battery company to produce high-safety composite conductive materials [10] - Xianju Pharmaceutical received drug registration for Progesterone Soft Capsules, used for treating functional disorders due to luteal deficiency [11] - Lanhua Kecai's subsidiary reported a temporary production halt, with the resumption date yet to be determined [13] Group 5 - Sinopharm Modern's subsidiary received drug registration for Tocilizumab Tablets, used for treating rheumatoid arthritis and other conditions [15] - Shanghai Bank announced the resignation of its vice president due to organizational adjustments [17] - Shanghai Pharmaceutical's Ephedrine Injection passed the consistency evaluation for generic drugs [19] Group 6 - Rundu Co., Ltd. received drug registration for Amlodipine and Olmesartan Tablets, aimed at treating hypertension [21] - Zhong'an Technology announced that 61 million shares held by its controlling shareholder will be auctioned [23] - Shanghai Washba plans to purchase patent assets and establish two subsidiaries focused on hydrogen energy and solid-state battery technologies [25] Group 7 - Nuo Cheng Jianhua's new drug Tafasitamab received approval for treating relapsed/refractory diffuse large B-cell lymphoma [26] - Benli Technology plans to use up to 200 million yuan of idle funds for cash management and financial investments [28] - Taiji Co., Ltd. intends to use 60 million yuan of idle funds to purchase financial products [29] Group 8 - Haishi Co. announced that its innovative drug Anreke Fen Injection received drug registration for treating postoperative pain [32] - Yulong Co. will have its stock delisted on May 27, 2025, following a decision by the Shanghai Stock Exchange [36] - Weifu High-Tech plans to establish a joint venture with Shanghai Baolong Automotive Technology [38] Group 9 - Xichang Electric Power expects a net profit reduction of approximately 5.4 million yuan due to adjustments in the time-of-use electricity pricing mechanism [39] - Alter signed a contract worth 6.8 billion yen for the development and procurement of large truck EV kits [41] - Zhonglian Heavy Industry plans to acquire controlling stakes in its financing leasing subsidiary through public bidding [42] Group 10 - Sanyou Medical's executive plans to reduce holdings by up to 1.44% of the company's shares [43] - Hangyang Co. plans to establish a subsidiary for large modular cryogenic equipment manufacturing with an estimated investment of 557 million yuan [44] - FAW Fuwi received a notification for a dashboard project from a well-known new energy brand, with total sales expected to reach 1.06 billion yuan [45]

Group 1 - The legal opinion letter is issued by Allbright Law Offices regarding the cancellation of certain unvested restricted stock granted under Zhejiang Benli Technology Co., Ltd.'s 2024 Restricted Stock Incentive Plan [1][2] - The law firm confirms that the necessary procedures and approvals for the cancellation of the unvested restricted stock have been completed as of the date of the legal opinion [4][6][10] - The company has decided to cancel a total of 96,250 shares of restricted stock that were granted but not vested, due to the departure of two incentive targets and the failure to meet performance targets [8][10] Group 2 - The performance assessment for the first vesting period of the incentive plan was based on revenue and net profit targets, which were not met, resulting in a 0% vesting ratio for the company [8][10] - The company achieved a revenue of 708.83 million yuan and a net profit of 64.57 million yuan in 2024, which did not meet the required performance thresholds for the vesting of the restricted stock [8][10] - The board and the compensation and assessment committee have agreed that the cancellation of the unvested restricted stock complies with relevant laws and regulations, and does not harm the interests of shareholders [10]